Commentary
Scientific advances have resulted in a number of innovative and highly effective new options for cancer therapy within the last few years. Many of these therapies are targeted to those patients who are most likely to benefit, thus improving therapeutic effectiveness. The rising costs of many new therapies have, however, spurred stakeholder groups to develop "value frameworks" to assess the health care value of these therapies. Although it is clear that the cost of drugs is a growing concern, value frameworks that do not include all of the trade-offs involved in making a value assessment may provide an incomplete report to patients and could result in misuse of these frameworks. Therefore, the metrics included in value frameworks and how the metrics are measured must be transparent, and the end user of the value frameworks needs to be carefully considered as frameworks begin to evolve and mature. Five value frameworks are currently in development to assess the value of cancer therapies: The American Society of Clinical Oncology Value Framework, the European Society for Medical Oncology's Magnitude of Clinical Benefit Scale, the Institute for Clinical and Economic Review Value Assessment Framework, the Memorial Sloan Kettering Cancer Center's DrugAbacus, and the National Comprehensive Cancer Network Evidence Blocks [1] [2] [3] [4] [5] .
Several recent review articles compare these frameworks and highlight several issues, including the need for increased patient input and improved patient-centeredness [6, 7] . It is worth noting that these frameworks are being improved via incorporation of stakeholder feedback, and this perspective is meant to offer guiding considerations as they continue to evolve.
Patients with life-threatening illnesses, such as cancer, place a high value on prompt availability of new therapies. Value frameworks should recognize and account for the trade-offs inherent in drug development by ensuring that metrics, such as end points used to demonstrate safety and efficacy and clinical trial designs employed to evaluate new products, do not diminish patients' preferences in determining and receiving their optimal treatment or create unintended consequences in therapeutic research and development. For example, there may be increased tension between providing timely access to new treatments for patients and designing a drug development program to meet an arbitrary and population-based value standard rather than focusing on the benefits to defined individuals. In oncology, a traditional gold standard for demonstrating efficacy to justify FDA approval of a drug is an improvement in overall survival [8] . For drugs with the potential to fill an unmet medical need for a very serious, lifethreatening disease (i.e., drugs that provide a treatment where none exists or that may be superior to existing therapy), however, the FDA can grant accelerated approval. This approval is based on effects on an end point that is reasonably likely to predict a clinical benefit, such as tumor shrinkage or other intermediate end points, and which can be measured earlier than overall survival (21 CFR Part 314, Subpart H). This approach can provide seriously ill patients with earlier access to new drugs while postmarket studies are conducted to confirm clinical benefit, as opposed to requiring significantly longer and more limited access to premarket studies to demonstrate an effect on overall survival before the treatment becomes available to patients.
In some proposed value frameworks, a drug would be determined to be more valuable, and consequently would likely command a higher price, if it showed a significant effect on overall survival. Although this seems logical, it may penalize some of the more effective drugs currently available to cancer patients (e.g., precision medicine or targeted therapies), many of which have demonstrated unprecedented effects on response rates and disease control rates in the premarket setting such that a randomized trial to assess survival might not be acceptable to patients.
Tools that overemphasize overall survival while underemphasizing other outcomes that also matter to patients, such as reduction of tumor or symptom burden or reduction in hospital admissions, may inadvertently create an incentive structure that prioritizes the development of long-term clinical benefit data in the premarket setting at the expense of providing patients timely access to potentially beneficial treatments. When interventions are approved based on surrogate end points, it does create some uncertainty as to whether the surrogate end point will reflect improvements in overall survival.
There are instances where surrogate end points do not always equate to improvements in overall survival when analyzed in later, postmarket confirmatory trials. Value frameworks, however, should ensure patients are able to designate the level of uncertainty they are willing to accept as they use these frameworks to potentially guide their therapy decisions. Importantly, when these confirmatory data are available, value frameworks should quickly incorporate this information so patients have the most up-to-date information.
When options have been exhausted, patients want access to experimental therapies provided through innovative clinical trial designs. In addition to end point selection, the experimental design of a clinical research trial plays a role in balancing the optimal evaluation of a new intervention with patient access. Patients who had been treated with the standard of care might be allowed access to the investigational intervention once the primary end point has been met in some clinical trials. This approach, referred to as crossover, allows more of the study participants to have access to the intervention under study and is an example of how a patient-centric approach can positively influence clinical trial designs.
Crossover, however, can also result in loss of information about the clinical impact of any new interventions when compared with a more rigid clinical trial design in which crossover would not be allowed [9, 10] . If a value assessment is made by comparing the relative improvement in survival yielded by a new intervention to that of another, sponsors may inadvertently be driven to rely solely on premarket overall survival data; patients then may be denied the opportunity to crossover to make the intervention be perceived as more valuable in value assessment frameworks. Precluding crossover may result in a more clearly defined assessment of magnitude of benefit, but patients may also be less likely to participate in studies that prohibit crossover.
These examples are not intended to suggest that clinical end points, such as overall survival, should not be included as important components of value-based assessments of medical technologies. Understanding the long-term implications of providing and paying for new treatment options is necessary to improve health care for patients and ensure that it is accessible and affordable for society and for individuals. These scenarios demonstrate, however, that value framework metrics should be constructed in a flexible manner that ranks appropriate timely access as a component of value to encourage the development of treatments that address unmet medical needs and patient needs. To accomplish this goal, value frameworks should appraise the full spectrum of available evidence and employ appropriate methods to ensure they fairly capture the benefits of each therapy. The long-term value of an effective intervention also needs to reflect nonfinancial end points, such as impact on family and community, route of administration, and other functional elements, which may not easily be quantifiable in standard, short-term pecuniary terms. They should also evaluate the therapy's impact on the overall cost of care (e.g., physician visits, hospital care, surgery).
Some value frameworks do incorporate the use of the qualityadjusted life-years, which have become standard in economic evaluations that attempt to identify what is optimal for society. Quality-adjusted life-years may not, however, adequately capture what is important for individual decision making. Therefore, value frameworks directed toward patients should work to provide a tailored output based on the needs of the individual end user. Value frameworks could serve to promote the inclusion of these important patient-focused metrics in future trials to better accomplish this goal.
Until patient-reported outcomes are routinely captured in clinical trials, framework developers should consider other methods to collect this information. Methods could include less formalized, postmarket data collection to better understand if an intervention is having a positive impact on aspects of patients' lives that are not frequently collected in premarket clinical trials. The involvement of patients and their caregivers in identifying aspects of daily life that were undesirably interrupted by an illness could also help inform future value assessments of different interventions. For example, patients often note that a desired outcome of treatment is the ability to continue to work [11] . An intervention that consistently allows patients to return to work more quickly than an alternative may be more valuable to some patients and may positively inform their treatment decisions.
Frameworks should also be flexible in incorporating evolving information regarding the context of use, such as the future availability of additional treatments for the same condition, as well as in assessing the value associated with different uses of the product, such as in a different line of treatment, population subset, or indication [12] . Because the body of evidence on medical products continues to evolve after approval, the value of a treatment should not be a static measure that is assigned at a single time point but rather should be a dynamic measurement that incorporates new evidence collected in the postmarket setting through additional clinical trials or real-world use in clinical practice.
The incorporation of real-world evidence into value frameworks will facilitate the inclusion of long-term safety and effectiveness data and provide information as to how different products perform in patient populations that are typically excluded from clinical trials. Real-world evidence may also yield important insight into the tolerability of different products based on treatment adherence or dose modification patterns, information that is not always reflected on drug labels. Overall, realworld evidence can help ensure that value frameworks do not solely rely on the best average treatment effect by recognizing the heterogeneity that is associated with cancer. Conducting postmarket trials has challenges and limitations, but efforts are underway with the goal of uncovering long-term, longitudinal information that will help inform and optimize the use of new products [13, 14] .
As these value frameworks undergo improvements, developers should consider including patient input early and throughout the development process; incorporating molecular diagnostics into these frameworks to better integrate the concept of precision medicine; defining value and making it explicitly known to end V A L U E I N H E A L T H 2 0 ( 2 0 1 7 ) 2 8 3 -2 8 5 users; developing methodology to incorporate new data as they are rapidly produced in oncology drug development; and ensuring that frameworks align with improved understanding and reliability of surrogate end points and innovative trial designs.
In addition, these frameworks may ultimately help improve the dialogue between the drug industry and society as they continue to be refined and utilized. We recognize the complexity of assessing the value of new therapies, particularly in a rapidly evolving field like oncology, but it should not come at the cost of blocking patient access to potentially life-saving therapies or undermining their current treatments. Source of financial support: No funding was provided for this commentary.
